Pulished Date August, 2019
ID: 7150
Share on
Share on

Asia Pacific Parkinson’s Disease Treatment Market By Drug Class (Dopamine Receptor Antagonists, Mono Amine Oxidase Inhibitors, Carbidopa, Anticholinergics And Other Drug Classes), By Distribution Channel (Retailer Pharmacies, Hospital Pharmacies And Online Pharmacies), By Patient Care Setting (Clinics And Hospitals) And By Region (Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: August, 2019
ID: 7150
Pages: 145

Parkinson's disease is a long-term degenerative disorder of the central nervous system which chiefly affects the motor system. The symptoms usually come on slowly with time. In the earlier stages of the disease, the most obvious are rigidity, shaking, slowness of movement, and difficulty in walking. Thinking and behavioural problems may also occur. Dementia becomes common during the advanced stages of the disease. Anxiety and depression are also common occurring in more than a third of people with this disease. Other symptoms include sleep, sensory, and emotional problems.

Asia Pacific Parkinson’s Disease Treatment Market was worth USD 1.04 billion in 2018 and estimated to be growing at a CAGR of 6.79%, to reach USD 1.44 billion by 2023.

The cause of Parkinson's disease is usually unknown, but it is believed to involve both environmental and genetic factors. Those who have a family member affected are more likely to get the disease themselves. There is also a higher risk in people exposed to certain pesticides and among those who have had prior head injuries, while there is a reduced risk in tobacco smokers and those who drink tea or coffee. The motor symptoms of the disease result from the death of cells in the substantia nigra which is a region of the midbrain. This results in less amounts of dopamine in these areas. Diagnosis of typical cases is mainly based on symptoms, with tests such as neuroimaging  which is used to rule out other diseases.

The driving factors of Asia Pacific Parkinson’s Disease Treatment market are  growth in aging population and the associated increase in the prevalence of parkinson’s disease and government funding for research. However, the market is constrained by factors such as availability of alternative options for the Parkinson’s disease management.

The Asia Pacific Parkinson’s Disease Treatment market is segmented based on drug class into dopamine receptor antagonists, mono amine oxidase inhibitors, carbidopa, anticholinergics and other drug classes. Carbidopa has the largest share in the segment. On the basis of distribution channel, the market is divided into retailer pharmacies, hospital pharmacies and online pharmacies. Hospital pharmacies has the largest share in the segment. By patient care setting, the market is classified into clinics and hospitals. In this segment, hospitals has the largest share.

The Asia Pacific Parkinson’s Disease Treatment market is divided based on geography into India, China, Japan, Australia and other parts of the region. Asia Pacific has the third largest market for parkinson’s disease treatment in the world by share. It is also the fastest growing region in the world. Factors such as growing geriatric population and increasing government funding for research are expected to drive the market growth in the region. 

Some of the major players in the market are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Dopamine Receptor Antagonists   

                                                5.1.1.1 Pramipexole

                                                5.1.1.2 Ropinirole

                                                5.1.1.3 Apomorphine

                                                5.1.1.4 Rotigotine

                                5.1.2 Mono Amine Oxidase Inhibitors    

                                                5.1.2.1 Selegiline

                                                5.1.2.2 Rasagiline

                                5.1.3 Carbidopa

                                5.1.4 Anticholinergics    

                                5.1.5 Other Drug Classes              

                                5.1.6  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7  Market Attractiveness Analysis, By Drug Class        

                                5.1.8  Market Share Analysis, By Drug Class         

                5.2 Distribution Channel                               

                                5.2.1 Retailer Pharmacies            

                                5.2.2 Hospital Pharmacies            

                                5.2.3 Online Pharmacies               

                                5.2.4 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.2.5 Market Attractiveness Analysis, By Distribution Channel    

                                5.2.6 Market Share Analysis, By Distribution Channel      

                5.3 Patient Care Setting                

                                5.3.1 Clinics        

                                5.3.2 Hospitals  

                                5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting       

                                5.3.4  Market Attractiveness Analysis, By Patient Care Setting    

                                5.3.5  Market Share Analysis, By Patient Care Setting      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Drug Class

                                                6.1.3.2 By Distribution Channel

                                                6.1.3.3 By Patient Care Setting

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Drug Class

                                                6.1.4.2 By Distribution Channel

                                                6.1.4.3 By Patient Care Setting

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Drug Class

                                                6.1.5.2 By Distribution Channel

                                                6.1.5.3 By Patient Care Setting

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Teva                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis AG                                

                8.3 GSK                                

                8.4 AbbVie                         

                8.5 Merck                           

                8.6 Boehringer Ingelheim                            

                8.7 Impax Laboratories                 

                8.8 Lundbeck                    

                8.9 Sun Pharma                                

                8.10 Wockhardt                               

                8.11 UCB                             

                8.12 Valeant Pharmaceuticals                    

                8.13 Acadia                        

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of By Drug Class type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Parkinson’s Disease Treatment Market By Drug Class , From 2018-2023( USD Million )
  2. Asia Pacific Dopamine Receptor Antagonists Market By Region, From 2018-2023( USD Million )
  3. Asia Pacific Mono Amine Oxidase Inhibitors Market By Region, From 2018-2023( USD Million )
  4. Asia Pacific Carbidopa Market By Region, From 2018-2023( USD Million )
  5. Asia Pacific Anticholinergics  Market By Region, From 2018-2023( USD Million )
  6. Asia Pacific Other Drug Classes Market By Region, From 2018-2023( USD Million )
  7. Asia Pacific Parkinson’s Disease Treatment Market By Distribution Channel , From 2018-2023( USD Million )
  8. Asia Pacific Retailer Pharmacies Market By Region, From 2018-2023( USD Million )
  9. Asia Pacific Hospital Pharmacies  Market By Region, From 2018-2023( USD Million )
  10. Asia Pacific Online Pharmacies Market By Region, From 2018-2023( USD Million )
  11. Asia Pacific Parkinson’s Disease Treatment Market By Patient Care Setting, From 2018-2023( USD Million )
  12. Asia Pacific Clinics  Market By Region, From 2018-2023( USD Million )
  13. Asia Pacific Hospitals Market By Region, From 2018-2023( USD Million )
  14. Japan Parkinson’s Disease Treatment Market By Drug Class , From 2018-2023( USD Million )
  15. Japan Parkinson’s Disease Treatment Market By Distribution Channel , From 2018-2023( USD Million )
  16. Japan Parkinson’s Disease Treatment Market By Patient Care Setting, From 2018-2023( USD Million )
  17. China Parkinson’s Disease Treatment Market By Drug Class , From 2018-2023( USD Million )
  18. China Parkinson’s Disease Treatment Market By Distribution Channel , From 2018-2023( USD Million )
  19. China Parkinson’s Disease Treatment Market By Patient Care Setting, From 2018-2023( USD Million )
  20. India Parkinson’s Disease Treatment Market By Drug Class , From 2018-2023( USD Million )
  21. India Parkinson’s Disease Treatment Market By Distribution Channel , From 2018-2023( USD Million )
  22. India Parkinson’s Disease Treatment Market By Patient Care Setting, From 2018-2023( USD Million )
  23. Australia Parkinson’s Disease Treatment Market By Drug Class , From 2018-2023( USD Million )
  24. Australia Parkinson’s Disease Treatment Market By Distribution Channel , From 2018-2023( USD Million )
  25. Australia Parkinson’s Disease Treatment Market By Patient Care Setting, From 2018-2023( USD Million )
  26. South Korea Parkinson’s Disease Treatment Market By Drug Class , From 2018-2023( USD Million )
  27. South Korea Parkinson’s Disease Treatment Market By Distribution Channel , From 2018-2023( USD Million )
  28. South Korea Parkinson’s Disease Treatment Market By Patient Care Setting, From 2018-2023( USD Million )

Please wait. . . . Your request is being processed

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample